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Abstract
Objective : The aim of the present study was to assess the association of leukocyte count and high sensitivity 
C-Reactive protein (hsCRP) with metabolic abnormalities in subjects with normal glucose tolerance.
Methods : Subjects with Normal Glucose Tolerance (NGT) (n = 865) were recruited from the Chennai Urban Rural 
Epidemiology Study [CURES]. Standard methods were used for assessing hsCRP [Nephelometry, in a subset] and 
leukocytes [Flowcytometry, Sysmex SF-3000].  Insulin resistance was calculated using the Homeostasis Assessment 
model (HOMA-IR).
Results : Body mass index, waist circumference, systolic and diastolic blood pressure, fasting plasma glucose, HbA1c, 
serum cholesterol, LDL cholesterol, HOMA IR and hsCRP increased significantly with increasing tertiles of leukocyte 
count [p for trend < 0.001]. Both leukocyte count and hsCRP showed a positive correlation with cardiovascular risk 
factors. Leukocyte count showed a positive correlation with hsCRP [p=0.008]. Both mean leukocyte count [p<0.001] 
and hsCRP [p=0.04] were higher in subjects with Metabolic Syndrome (MS), which increased with increase in number 
of metabolic abnormalities [p for trend <0.001]. Regression models showed leukocyte count [p<0.001] and hsCRP 
[p=0.03] to be associated with MS, even after adjusting for age and gender. 
Conclusion : A significant association exists between systemic inflammation [leukocyte count and hsCRP] and MS/
cardiovascular risk factors in Asian Indians even among non-diabetic subjects. ©
INTRODUCTION
Increased predisposition to diabetes and coronary artery disease (CAD) among Asian Indians has long been 
recognized.1-2 Insulin resistance is considered to be one 
of the underlying causes for both glucose intolerance 
and CAD.3 Insulin resistance clusters with many other 
metabolic abnormalities, which are collectively known as 
metabolic syndrome [MS].3 Recent studies have reported 
that inflammatory markers like leukocyte count4 and 
high sensitivity C-reactive protein [hsCRP]5 are associated 
with cardiovascular risk factors and MS. Indeed, elevated 
leukocyte count has been reported to be a predictor 
of cardiovascular mortality independent of traditional 
cardiovascular risk factors.6 Leukocytes contribute to 
blood viscosity, release products that induce plaque 
rupture and thrombus formation,7 and play a role in 
endothelial dysfunction.8 Recent studies have also shown 
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leukocyte count to be positively associated with carotid 
atherosclerosis,9 a preclinical atherosclerotic marker and 
various components of MS and negatively associated 
with measures of insulin sensitivity. Prospective studies 
have indicated leukocyte count to be a predictor of type 
2 diabetes.10 
High hsCRP levels have been associated with a higher 
risk of cardiovascular morbidity and mortality in healthy 
subjects.5,11 Measurement of hsCRP has been shown to 
add to the predictive ability of the Framingham risk score.12 
Several studies have shown an association between hsCRP 
and the various components of metabolic syndrome, 
especially diabetes, obesity and CAD among Europeans.13-
15 
A recent analysis of global and regional mortality 
indicated that Asian Indians had the highest mortality rates 
due to ischemic heart disease.2,16 We earlier reported that 
hsCRP is associated with diabetes and CAD in Asian Indians.17 
However, there are hardly any studies on these ‘emerging’ 
risk factors in subjects with Normal Glucose Tolerance [NGT]. 
Therefore, we examined whether elevations of leukocyte 
count and hsCRP exhibit any association with cardiovascular 
risk factors and metabolic syndrome in Asian Indian subjects 
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with NGT.
RESEARCH DESIGN aND METHODS
Study subjects were recruited from the Chennai 
Urban Rural Epidemiology Study (CURES), an ongoing 
epidemiological study conducted on a representative 
population (aged ≥ 20 years) of Chennai (formerly Madras), 
the fourth largest city in India. The methodology of the 
study has been published elsewhere.18 Briefly, in Phase 1 
of the urban component of CURES, 26,001 individuals were 
recruited based on a systematic random sampling technique, 
which is described in our website www.drmohansdiabetes.
com (under the link “Publications”). Fasting capillary blood 
glucose was determined using a One Touch Basic glucose 
meter (Life scan, Johnson & Johnson, Milpitas, California, 
USA) in all subjects. Subjects were classified as ‘known 
diabetic subjects’ if they stated that they had diabetes and 
were on the treatment.
In Phase 2 of CURES, all the known diabetic subjects 
(n=1529) were invited to the centre for detailed studies 
on vascular complications, and 1382 responded [response 
rate 90.3%]. From the rest of the study subjects, 10% of 
newly diagnosed diabetic subjects (n = 320; response rate, 
98.8%), 15% of subjects with impaired fasting glucose (n 
= 866; response rate, 99.1%), and 10% of subjects with 
normal fasting glucose (n = 1494; response rate, 97.0%) 
were recruited. Those who were confirmed by OGTT to have 
2hour post glucose value < 7.8 mmol/L [140 mg/dl]  based 
on WHO consulting group criteria19 were labeled as ‘normal 
glucose tolerance’ [NGT].  A subset of subjects with NGT 
[n=1000] were randomly selected to participate in this study 
and 865 responded [response rate: 86.5%]. The inclusion 
criteria were: absence of infectious or inflammatory diseases 
and not on statins or aspirin. Institutional ethical committee 
approval was obtained for the study and informed consent 
was obtained from all study subjects.
Anthropometric measurements
Anthropometric measurements including weight, height 
and waist measurements were obtained using standardized 
techniques as detailed elsewhere.18 The body mass index 
(BMI) was calculated using the formula, weight (kg) / height 
(m2). Blood pressure was recorded in the sitting position 
in the right arm to the nearest 2mm Hg with a mercury 
sphygmomanometer (Diamond Deluxe BP apparatus, Pune, 
India). Two readings were taken 5 minutes apart and the 
mean of the two was taken as the blood pressure. 
Biochemical parameters
Fasting plasma glucose (glucose oxidase-peroxidase 
method), serum cholesterol (cholesterol oxidase-peroxidase-
amidopyrine method) serum triglycerides (glycerol 
phosphate oxidase-peroxidase-amidopyrine method) 
and HDL cholesterol (direct method-polyethylene glycol-
pretreated enzymes) were measured using Hitachi-912 
Autoanalyser (Hitachi, Mannheim, Germany). The intra and 
inter assay co-efficient of variation for the biochemical assays 
ranged between 3.1% to 7.6%. Low-density lipoprotein 
(LDL) cholesterol was calculated using the Friedewald 
formula. Glycated haemoglobin (HbA1C) was estimated 
by high-pressure liquid chromatography using the Variant 
machine (Bio-Rad, Hercules, Calif., USA).  The intra and inter 
assay co-efficient of variation of HbA1C was <10%. 
Measurement of hsCRP and Leukocyte count
The plasma concentrations of hsCRP were measured, in 
a subset of 192 subjects, by a high sensitive nephelometric 
assay using a monoclonal antibody to CRP coated on 
polysterene beads (Dade Behring, Marburg, Germany). The 
intra-assay and the inter-assay co-efficient of variation for 
hs-CRP were 4.2% and 6.8 % respectively and the lower 
detection limit was 0.17 mg/l. Leukocyte count was assessed 
using flowcytometry [Sysmex – SF3000, Japan]. The intra 
and inter assay co-efficient of variation of leukocyte count 
was <10%.
Definitions and diagnostic criteria
Metabolic abnormalities: Hypercholesterolaemia 
[serum cholesterol ≥ 200 mg/dl or subjects who self 
reported hypercholesterolemia and were on statins], 
hypertriglyceridaemia [serum triglycerides ≥ 150 mg/dl or 
subjects who self reported hypertriglyceridemia and were 
on drugs for hypertriglyceridemia] and low HDL cholesterol 
[males: HDL cholesterol <40 mg/dl, females: HDL cholesterol 
<50 mg/dl] were diagnosed based on ATPIII guidelines.20 
Metabolic syndrome was diagnosed based on modified 
ATPIII guidelines,20 if any three of the following abnormalities 
were present: abdominal obesity [defined as waist 
circumference ≥ 90 cm for males and ≥ 80 cm for females 
according to modified Asia Pacific WHO guidelines,21 high 
blood pressure [systolic blood pressure (SBP) ≥ 130 mmHg 
or diastolic blood pressure (DBP) ≥ 85mmHg or subjects who 
self reported hypertension and were on antihypertensives], 
hypertriglyceridaemia or low HDL cholesterol. Insulin 
resistance was calculated using the homeostasis assessment 
model (HOMA-IR) using the formula: fasting insulin (lu/mL) 
fasting glucose (mmol/L)/22.5.
Statistical analysis
Student’s t test or one-way ANOVA [with Tukey’s 
HSD] as appropriate was used to compare groups for 
continuous variables and Chi-square test or Fisher’s Exact 
test as appropriate was used to compare proportions. 
Study subjects were categorized into tertiles of leukocyte 
count; unequal numbers were found in the tertiles, due to 
decimals. Pearson’s correlation analysis was carried out to 
determine the correlation of leukocyte count and hsCRP 
with cardiovascular risk factors. Logistic regression analysis 
was carried out using MS as the dependent variable and 
other risk factors as independent variables. All analysis 
was done using Windows-based SPSS statistical package 
(Version 10.0, Chicago) and p values <0.05 were taken as 
significant.
RESULTS
The clinical and biochemical characteristics of the study 
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subjects stratified according to tertiles of leukocyte count 
are shown in Table 1. Body mass index, waist circumference, 
systolic and diastolic blood pressure, fasting plasma glucose, 
HbA1c, serum cholesterol, LDL cholesterol, HOMA IR and 
hsCRP increased significantly with increasing tertiles of 
leukocyte count [p for trend <0.001]. 
Table 2 presents the results of the Pearson’s correlation 
analysis of leukocyte count and hsCRP with cardiovascular 
risk factors. Leukocyte count had a positive associated 
with body mass index [p<0.001], waist circumference 
[p<0.001], systolic and diastolic blood pressure [p<0.01], 
fasting plasma glucose [p=0.02], HbA1c [p=0.003], 
serum cholesterol [p<0.001], triglycerides [p=0.006], LDL 
cholesterol [p<0.001] and HOMA IR [p<0.001] and a negative 
association with HDL cholesterol [p=0.04].  hsCRP was 
positively associated with body mass index [p<0.001], waist 
circumference [p=0.004], systolic blood pressure [p=0.02], 
fasting plasma glucose [p=0.003], HbA1c [p=0.002] and 
HOMA IR [p=0.002].
In multiple linear regression analysis, hsCRP showed an 
association with leukocyte count [β =0.131, p=0.008] even 
after adjusting for age and gender [β =0.128, p=0.011].
Mean levels of leukocyte count and hsCRP in subjects 
with and without varying metabolic abnormalities are 
presented in Table 3.  Leukocyte count was higher in subjects 
with abdominal obesity [p<0.001], hypertriglyceridemia 
[p=0.011], low HDL cholesterol [p=0.002] and metabolic 
syndrome [p<0.001] compared to their counterparts 
without the respective metabolic abnormalities.
Subjects with abdominal obesity [p=0.003] and MS 
[0.04] had significantly higher levels of hsCRP compared 
those without these abnormalities.  Though mean hsCRP 
levels were higher in subjects with elevated fasting plasma 
glucose, hypertriglyceridemia, low HDL cholesterol and 
hypertension compared to their counterparts with normal 
levels of respective parameters, the differences did not reach 
statistical significance.
There was a linear increase in the mean values of 
leukocyte count with increase in number of components of 
MS [p for trend <0.001] [Fig. 1].  hsCRP levels also increased 
with increase in number of components of MS [no metabolic 
abnormality: 1.3 ± 0.5, one metabolic abnormality: 1.9 ± 
1.0,  two metabolic abnormalities: 2.2 ± 1.1 , ≥ 3 metabolic 
abnormalities: 2.7 ± 1.4 mg/L] [p for trend <0.001] [Fig. 2].
Logistic regression analysis using MS as dependant 
variable showed that leukocyte count had a strong 
association with MS [Odds Ratio (OR): 1.27, 95% confidence 
interval (CI): 1.14 – 1.42, p<0.001]. This association remained 
statistically significant even after adjustment for age and 
Table 1 : Clinical characteristics of study subjects in tertiles of 
leukocyte count
Parameters 1st Tertile 2nd Tertile 3rd Tertile 
 [n= 288] [n= 289] [n= 288]
Leukocyte count 3.15 – 6.48 6.49 – 7.89 >7.9  
 [x103/ml]  
Age [years] 39 ± 13 40± 12 41± 12
Male n [%] 144 [50.0] 120 [42.0] 92 [31.9]
Body mass 22 ± 4.0 24 ± 4.0** 25 ± 5.0**# 
 index [kg/m2] 
Waist circumference 82.1 ± 11.3 85.2 ± 10.8** 85.8 ± 
12.1** 
 [cm]
Systolic blood 115 ± 14 119 ± 17** 120 ± 17** 
 pressure [mm Hg] 
Diastolic blood 73 ± 10 75 ± 10* 76 ± 10** 
 pressure [mm Hg] 
Fasting plasma 84 ± 8 85 ± 8 86 ± 9* 
 glucose [mg/dl] 
HbA1c [%] 5.5 ± 0.4 5.6 ± 0.4 5.6 ± 0.5*
HOMA IR 1.5 ± 1.0 1.9 ± 1.2** 2.0 ± 1.3**
Total cholesterol 171 ± 35 181 ± 37** 183 ± 38** 
 [mg/dl] 
Serum triglycerides 110 ± 64 116 ± 70 121 ± 62 
 [mg/dl] 
LDL cholesterol 105 ± 29 114 ± 32** 116 ± 32** 
 [mg/dl] 
HDL cholesterol 
 [mg/dl] 45 ± 12 43 ± 9 43 ± 9
HsCRP [mg/L] 1.08 1.14   1.82*#@ 
 ^ [n= 192]  [n= 59] [n= 65] [n= 68]
^ Geometric mean. * P<0.01, ** P<0.001 compared to 1st tertile of 
leukocyte count. # p<0.05 compared to 2nd tertile of leukocyte count. @ 
Table 2 : Pearson correlation analysis of leukocyte count and 
hsCRP with cardiovascular risk variables 
             Leukocyte count    HsCRP
 r value p value r value p 
value
Age  0.019 0.582 0.031 0.671
Body mass index [BMI] 0.200 <0.001 0.326 <0.001
Waist circumference 0.137 <0.001 0.212 0.004
Systolic blood pressure 0.106 <0.01 0.161 0.026
Diastolic blood pressure 0.096 <0.01 0.010 0.888
Fasting plasma glucose 0.079 0.020 0.215 0.003
HbA1c 0.103 0.003 0.227 0.002
HOMA IR 0.167 <0.001 0.224 0.002
Serum cholesterol 0.150 <0.001 0.058 0.420
Serum triglycerides 0.094 0.006 0.024 0.739
HDL cholesterol - 0.069 0.044 - 0.087 0.230
LDL cholesterol 0.159 <0.001 0.113 0.118
hsCRP 0.190 0.008 - -
Table 3 : Mean levels of leukocyte count and hsCRP with              
metabolic abnormalities
Metabolic  Mean   P  Mean  P  
abnormalities  leukocyte value HsCRP  value 
  count  [mg/L] 
  [x103/ml]
Abdominal  Present  7.5 ± 1.5 < 0.001 2.6 ± 2.2 0.003 
 obesity Absent  7.0 ± 1.4  1.6 ± 1.1 
Hypertension Present  7.4 ± 1.4 0.113 2.3 ± 1.9 0.647
 Absent  7.2 ± 1.3  2.1 ± 1.6 
Hypertrigly- Present  7.5 ± 1.6 0.011 2.5 ± 1.9 0.308
 ceridemia Absent  7.2 ± 1.5  2.1 ± 1.5 
Low HDL Present  7.4 ± 1.5 0.002 2.3 ± 1.9 0.159 
 cholesterol Absent  7.1 ± 1.4  1.9 ± 1.5 
Metabolic Present  7.7 ± 1.5 < 0.001 2.7 ± 2.1 0.04 
 syndrome Absent  7.1 ± 1.4  2.0 ± 1.5
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gender [OR: 1.28, 95% CI: 1.15 – 1.44, p<0.001]. hsCRP was 
significantly associated with MS [Odds Ratio (OR): 1.14, 
95% confidence interval (CI): 1.00 – 1.32, p=0.04]. This 
association remained statistically significant even after 
adjusting for age and gender [OR: 1.16, 95% CI: 1.01 – 1.34, 
p=0.03] [Table 4]. 
DISCUSSION
The main findings of the study are that in Asian Indian 
subjects with NGT, both leukocyte count and hsCRP show an 
association with most cardiovascular risk factors and MS.
Earlier studies in the west have reported that leukocyte 
count and hsCRP are associated with MS, diabetes and 
CAD.6,7,10,11,17 This is the first study however to report on 
the association of both leukocyte count and hsCRP with 
cardiovascular risk factors and MS in an Asian Indian 
population and is significant because of the high prevalence 
of insulin resistance, diabetes and premature CAD in this 
ethnic group.2,22 
The contributory role of inflammatory markers in 
cardiovascular disease has been documented in several 
studies. Abdominal obesity is considered to be the main 
link between inflammation and metabolic disorders. 
Leukocyte count has been demonstrated to be associated 
with abdominal obesity in Pima Indians, Whites and Blacks.23 
Similarly, several studies have shown an association of hsCRP 
with abdominal obesity.17,24 This led to the suggestion that 
both leukocyte count and hsCRP play a major role in linking 
adiposity to diabetes and CAD. Our results corroborate 
these findings as both leukocyte count and hsCRP had a 
significant association with waist circumference. These data 
also support the hypothesis that subclinical inflammation 
could perhaps be a component of metabolic syndrome.
Earlier studies have reported that leukocyte count and 
hsCRP are increased in subjects with MS.13 In the CARDIA 
study, a significant positive association was observed 
between leukocyte count and systolic blood pressure and 
BMI, and a negative correlation with HDL-cholesterol.25 
Our results are in agreement with these findings. We also 
observed that body mass index and systolic blood pressure 
increased, while HDL cholesterol decreased with increase 
in tertiles of leukocyte count. 
 Targher et al26 investigated the association between 
leukocyte count and CAD risk factors, and reported that a 
higher leukocyte count was associated with clustering of 
components of metabolic syndrome. Similar results were 
observed in the present study in which both leukocyte 
count and hsCRP were increased in subjects with MS. We 
also observed that both showed a significant association 
with MS even after adjusting for age and gender. This 
indicates that normal subjects having increasing levels 
of both leukocyte count and hsCRP are more prone to 
cardiovascular risk. 
It was also observed that both leukocyte count and 
hsCRP increased with increase in number of metabolic 
abnormalities indicating a dose–response relationship 
between these risk factors and metabolic abnormalities. 
This relationship also suggests that subjects with a single 
MS component could have low-grade inflammation, 
which might intensify as the number of MS components 
increase. Similar results were found in a study on Japanese 
men, which reported that leukocyte count increased with 
increase in number components of MS.27
Although the mechanism by which the leukocyte 
Table 4 : Multiple logistic regression analysis
      Dependent variable: Metabolic syndrome
Parameter Odds  95% Confidence  P value 
 Ratio [OR] Interval [CI]
Leukocyte count
Unadjusted  1.27 1.14 – 1.2 <0.001
Adjusted for age 1.28 1.14 – 1.43 < 0.001
Adjusted for  
 age and gender
[Male=0, Female=1] 1.28 1.15 – 1.44 < 0.001
HsCRP 
Unadjusted 1.14 1.00–1.32 0.04
Adjusted for age 1.16 1.00 – 1.34 0.03
Adjusted for 
 age and gender
[Male=0, Female=1] 1.16 1.01 – 1.34  0.03
Error bars indicate SD.  *p<0.01, *p<0.001 compared to no abnormality. 
^p for trend <0.001
Fig.1: mean Leukocyte count in relation to number of metabolic 
abnormalities. 
Error bars indicate SD. *p<0.01 compared to no abnormality. ^p for 
trend <0.001
Fig. 2 : Mean hsCRP in relation to number of metabolic abnormalities.
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count is linked to MS remains unclear, there are several 
explanations. It has been suggested that the link could 
be through insulin resistance, which predisposes one to 
diabetes, MS and CAD.3 In this context, it is important note 
in our study that insulin resistance increased with increase 
in tertiles of leukocyte count. The mechanism underlying 
the strong relationship between leukocyte count and insulin 
resistance may be a subtle activation of the immune system, 
leading to increased expression of proinflammatory factors 
shown strongly associated with insulin resistance. Another 
explanation for the link between leukocyte and MS could be 
through vascular endothelial cells. Vascular endothelial cells 
are activated by the presence of atherosclerotic risk factors, 
such as hypertension, hyperlipidemia and hyperglycemia. 
Endothelial cells produce intracellular adhesion molecule 
- 1, an adhesion molecule, which causes leukocyte to 
adhere to the vascular wall, after which they can penetrate 
the vascular endothelium and produce new cytokines 
and chemokines. Cytokines then activate the leukocyte 
and cells comprising the vascular wall, promoting platelet 
aggregation and thrombus formation.28 Proinflammatory 
cytokines are also known to increase the leukocyte count, 
which in turn could further exacerbate the inflammation. 
Further studies are necessary to elucidate the role of 
leukocytes and hsCRP in the mechanisms underlying MS.
One of the limitations of our finding is that being a cross-
sectional study, a cause-and-effect relation of leukocyte 
count and hsCRP with metabolic syndrome cannot be 
determined. However the strength of the study is that it is 
a population-based study and the first in Asian Indians who 
are a high risk group for both diabetes and CAD.
In conclusion, this study reports that among Asian Indians 
who are known to have high risk of premature coronary 
artery disease and diabetes, a significant association exists 
between both leukocyte count and hsCRP with metabolic 
syndrome and cardiovascular risk factors even among 
non-diabetic subjects. This study is significant because in 
developing countries like India where hsCRP measurement 
could be more expensive, even a simple leukocyte count 
- which represents systemic inflammation, could serve as 
a risk marker for cardiovascular disease, if infections were 
excluded.
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